Morphology of proliferating and non-proliferating tumor cell nuclei in glioblastomas correlates with preoperative data from proton-MR-spectroscopy

Neuropathology

Volumn 24, Issue 3, 2004, Pages 172-182

  Nafe, Reinhold ^a   Herminghaus, Sebastian ^a   Pilatus, Ulrich ^a   Hattingen, Elke ^a   Marquardt, Gerhard ^a   Schlote, Wolfgang ^a   Lanfermann, Heinrich ^a   Zanella, Friedhelm ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Brain tumor; Glioblastoma; Ki 67; Morphometry; Spectroscopy

Indexed keywords

CREATINE; KI 67 ANTIGEN; N ACETYLASPARTIC ACID; PARAFFIN; TUMOR MARKER;

ARTICLE; BRAIN TUMOR; CELL LEVEL; CELL NUCLEUS; CELL PROLIFERATION; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISCRIMINANT ANALYSIS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MORPHOMETRICS; PARAMETER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; TISSUE SECTION; TUMOR CELL;

CELL NUCLEUS; CELL PROLIFERATION; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PREOPERATIVE CARE; PROTONS; STATISTICS, NONPARAMETRIC;

EID: 4644303113     PISSN: 09196544     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1789.2004.00547.x     Document Type: Article

References (48)

1. Nafe R, Herminghaus S, Raab P et al. Preoperative proton-MR spectroscopy of gliomas - correlation with quantitative nuclear morphology in surgical specimen. J Neurooncol 2003; 63: 233-245.
2. Siemens AG. Magnetom Vision Application-Manual, Numaris Version 31 C. Germany: Erlangen, 1999.
3. Haase A, Frahm J, Hänicke W, Matthei D. 1H NMR chemical shift selective (CHESS) imaging. Phys Med Biol 1985; 30: 341-344.
4. de Beer R, van den Boogaart A, van Ormondt D et al. Application of time domain fitting in the quantification of in vivo 1H spectroscopic imaging data sets. NMR Biomed 1992; 5: 171-178.
5. Klunk WE, Xu CJ, Panchalingham K, McClure RJ, Pettegrew JW. Analysis of Magnetic resonance spectra by mole percent: comparison of absolute units. Neurobiol Aging 1994; 15: 133-140.
6. MRUI. Magnetic Resonance User Interface. The MRUI Project, 2001. [Cited 1 March 2001.] Available from URL: http://www.mrui.uab.es/mrui/mruiHomePage.html
7. Petrow OAC, Spencer DD, Alger JR, Prichard JW. High field proton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology 1989; 39: 1197-1202.
8. Van der Veen JWC, De Beer PR, Luyten PR, Van Ormondt D. Accurate quantification of in vivo 31P-NMR signals using the variable projection method and prior knowledge. Magn Reson Med 1988; 6: 92-98.
9. Kleihues P, Burger PC, Collins VP, Newcomb EW, Ohgaki H, Cavenee WK. Glioblastoma. In: Kleihues P, Cavenee WK, (eds) Pathology and Genetics of Tumours of the Nervous System. Lyon. IARC Press, 2000; 29-39.
10. Nafe R, Schlote W, Schneider B. Planimetric characterization of tumor cell nuclei in astrocytic tumors - comparison of different tumor grades according to the WHO-classification. E J Pathol (Serial online) 2000 December; 6(4): (1 screen). Available from URL: http://ejpath.amu.edu.pl/ejp6-4/004-01. html
11. Nafe R, Schlote W, Schneider B. Shape analysis of tumor cell nuclei in ependymomas by means of Fourier-analysis. Anal Quant Cytol Histol 2000; 6: 475-482.
12. Nafe R, Glienke W, Schlote W, Schneider B. EGFR gene-amplification in glioblastomas - is there a relation with morphology of tumor cell nuclei and proliferative activity? Anal Quant Cytol Histol 2001; 23: 135-143.
13. Nafe R, Franz K, Schlote W, Schneider B. Quantitative investigation of nuclear morphology in glioblastomas and its relation to survival time. Clin Neuropathol 2003; 22: 129-136.
14. Nafe R, Herminghaus S, Raab P et al. Correlation between preoperative magnetic resonance spectroscopic data on high-grade gliomas and morphology of Ki67-positive tumor cell nuclei. Anal Quant Cytol Histol 2003; 25: 131-138.
15. Nafe R, Schlote W. Topometric analysis of diffuse astrocytomas. Anal Quant Cytol Histol 2003; 25: 12-18.
16. Nafe R, Schlote W, Schneider B. Data analysis for comparative histometry in pathology - I. Classification procedures and other statistical methods. E J Pathol (Serial online) 2000 June; 6(2): (3 screens). Available from URL: http://ejpath.amu.edu.pl/ejp6-2/002-03.html
17. Kubas B, Tarasów E, Dzienis W et al. Magnetic resonance proton spectroscopy in neurooncology - preliminary report. Neurol Neurochir Pol 2001; 35 (Suppl. 5): 90-100.
18. Möller-Hartmann W, Herminghaus S, Krings T et al. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiol 2002; 44: 371-381.
19. Tedeschi G, Lundbom N, Raman R et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997; 87: 516-524.
20. Bendszus M, Warmuth-Metz M, Klein R et al. MR spectroscopy in gliomatosis cerebri. Am J Neuroradiol 2000; 21: 375-380.
21. Dowling C, Bollen AW, Noworolski SM et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimen. Am J Neuroradiol 2001; 22: 604-612.
22. Galanaud D, Chinot O, Nicoli F et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg 2003; 98: 269-276.
23. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt AW. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002; 222: 715-721.
24. Norfray JF, Tomita T, Byrd SE, Ross BD, Berger PA, Miller RS. Clinical impact of MR spectroscopy when MR imaging is indeterminate for pediatric brain tumors. Am J Radiol 1999; 173: 119-125.
25. Norfray JF, Darling C, Byrd S et al. Short TE proton MRS and neurofibromatosis type 1 intracranial lesions. J Comput Assist Tomogr 1999; 23: 994-1003.
26. Yu HW, Tanabe S, Yamaki T, Harada K, Hashi K. Diagnosis of brain tumor with proton MR spectroscopy - the quantification of gliomas compared with normal brain. No Shinkei Geka 2000; 28: 1063-1069.
27. Croteau D, Scarpace L, Hearshen D et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative analyses of patients with untreated glioma. Neurosurg 2001; 49: 823-829.
28. Graves EE, Nelson SJ, Vigneron DB et al. A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. Neurosurg 2000; 46: 319-328.
29. Lazareff JA, Gupta RK, Alger JR. Variation of post-treatment H-MRSI choline signal intensity in pediatric gliomas. J Neuro-Oncol 1999; 41: 291-298.
30. McKnight TR, dem Busche MH, Vigneron DB et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 2002; 97: 794-802.
31. Preul MC, Caramanos Z, Villemure JG et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurg 2000; 46: 306-318.
32. Rock JP, Hearshen D, Scarpace L et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurg 2002; 51: 912-920.
33. Gupta RK, Cloughesy TF, Sinha U et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neuro-Oncol 2000; 50: 215-226.
34. Shimizu H, Kumabe T, Shirane R, Yoshimoto T. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labelling index in gliomas. Am J Neuroradiol 2000; 21: 659-665.
35. Tamiya T, Kinoshita K, Ono Y, Matsumoto K, Furuta T, Ohmoto T. Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas. Neuroradiol 2000; 42: 333-338.
36. Go KG, Kamman RL, Pruim J et al. On the principles underlying the diagnosis of brain tumours - a survey article. Acta Neurochir (Wien) 1995; 135: 1-11.
37. Miller BL. A review of chemical issues in 1H-NMR spectroscopy: N-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991; 4: 47-52.
38. Demaerel P, Johannik K, vanHecke P et al. Localized 1H-NMR spectroscopy in fifty cases of newly diagnosed intracranial tumors. J Comput Assist Tomogr 1991; 15: 67-76.
39. Luyten PR, Marien AJ, Heindel W et al. Metabolic imaging of patients with intracranial tumors: 1H-MR spectroscopic imaging and PET. Radiology 1990; 176: 791-799.
40. Miller BL, McBride D, Riedy G, Caron M, Lipcamon J, O'Brien D. Changes in brain choline in 1H-MR spectroscopy. Bull Clin Neurosci 1990; 55: 115-122.
41. Miller BL, Chang L, Booth RA et al. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci 1996; 58: 1929-1935.
42. Tarnawski R, Sokol M, Pieniazek P et al. 1H-MRS in vivo predicts the early treatment outcome of postoperative radiotherapy for malignant gliomas. Int J Radiat Oncol Biol Phys 2002; 52: 1271-1276.
43. Aiken NR, Gillies RJ. Phosphomonoester metabolism as a function of cell proliferative status and exogeneous precursors. Anticancer Res 1996; 16: 1393-1397.
44. Bhakoo KK, Williams SR, Florian CL, Land H, Noble MD. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res 1996; 56: 4630-4635.
45. Chang L, McBride D, Miller BL et al. Localized in vivo 1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J Neuroimaging 1995; 5: 157-163.
46. Hunt AN, Clark GT, Attard GS, Postle AD. Highly saturated endonuclear phosphatidylcholine is synthesized in situ and collocated with CDP-choline pathway enzymes. J Biol Chem 2001; 276: 8492-8499.
47. Byrd SE, Tomita T, Palka PS, Darling CF, Norfray JP, Fan J. Magnetic resonance spectroscopy (MRS) in the evaluation of pediatric brain tumors, part II: clinical analysis. J Natl Med Assoc 1996; 88: 717-723.
48. Falini A, Calabrese G, Origgi D et al. Proton magnetic resonance spectroscopy and intracranial tumours: clinical perspectives. J Neurol 1996; 243: 706-714.